

**Amendment Y1  
for Partner Project Agreement P-004**

This Amendment Y1 is entered into as of the 1st day of July 2022 by and between the Science and Technology Center in Ukraine (Center), the Institute of Endocrinology and Metabolism Academy of Medical Science of Ukraine (Recipient), and the National Cancer Institute of the United States of America (Partner).

This Amendment Y1 amends the Partner Project Agreement P-004 (Agreement), which commenced on January 1, 1998, together with Partner Project Agreement P-004A, which commenced on July 1, 1998, Partner Project Agreement P-004AA, which commenced on July 1, 1999, with Amendment for Partner Project Agreement P-004, which commenced on October 1, 1999, and Partner Project Agreement P-004B, which commenced on July 1, 2000, with Amendment C for Partner Project Agreement P-004, which commenced on April 1, 2001; with Amendment D for Partner Project Agreement P-004, which commenced on April 1, 2002; with Amendment E for Partner Project Agreement P-004, which commenced on April 1, 2003; with Amendment E1 for Partner Project Agreement P-004, which commenced on May 26, 2003; with Amendment E2 for Partner Project Agreement P-004, which commenced on 24 February, 2004; with Amendment F for Partner Project Agreement P-004, which commenced on April 1, 2004; with Amendment G for Partner Project Agreement P-004, which commenced on April 1, 2005; with Amendment H for Partner Project Agreement P-004, which commenced on April 1, 2006; with Amendment I for Partner Project Agreement P-004, which commenced on April 1, 2007; with Agreement of variation for Partner Project Agreement P-004, which commenced on April 1, 2008; with Agreement of variation for Partner Project Agreement P-004, which commenced on July 1, 2008; with Agreement of variation for Partner Project Agreement P-004, which commenced on September 1, 2008; with Amendment J for Partner Project Agreement P-004, which commenced on December 1, 2008; with Amendment K for Partner Project Agreement P-004, which commenced on December 1, 2009; with Amendment L for Partner Project Agreement P-004, which commenced on December 1, 2010; with Agreement of variation For Partner Project Agreement P-004L, which commenced on February 1, 2011, and with Agreement of variation For Partner Project Agreement P-004L, which commenced on May 1, 2011; with Amendment M for Partner Project Agreement P-004, which commenced on December 1, 2011; with Amendment N for Partner Project Agreement P-004, which commenced on December 1, 2011; with Agreement of variation For Partner Project Agreement P-004M, which commenced on December 1, 2012; with Agreement of variation 1 For Partner Project Agreement P-004M, which commenced on March 1, 2013; with Agreement of variation 2 For Partner Project Agreement P-004M, which commenced on June 1, 2013; and with Agreement of variation 3 For Partner Project Agreement P-004M, which commenced on September 1, 2013; with Amendment O for Partner Project Agreement P-004, which commenced on September 20, 2013; with Agreement of variation For Partner Project Agreement P-004O, which commenced on March 20, 2014; with Amendment P1 for Partner Project Agreement P-004, which commenced on June 6, 2014; with Agreement of variation For Partner Project Agreement P-004N, which commenced on January 1, 2015; with Agreement of variation For Partner Project Agreement P-004P, which commenced on May 1, 2015; with Agreement of variation For Partner Project Agreement P-004P1, which commenced on May 1, 2015; with Amendment Q for Partner Project Agreement P-004, which commenced on August 1, 2015; with Agreement of variation For Partner Project Agreement P-004Q, which commenced on November 1, 2015; with Agreement of variation For Partner Project Agreement P-004N, which commenced on November 1, 2015; with Amendment R for Partner Project Agreement P-004, which commenced on May 1, 2016; with Amendment R1 for Partner Project Agreement P-004, which commenced on May 1, 2016; and with Amendment N1 for Partner Project Agreement P-004, which commenced on May 1, 2016; with Amendment S for Partner Project Agreement P-004, which commenced on May 1, 2017; with Amendment S1 for Partner Project Agreement P-004, which commenced on August 1, 2017; with Amendment S2 for Partner Project Agreement P-004, which commenced on November 1, 2017; with Amendment T for Partner Project Agreement P-004, which commenced on May 1, 2018; with Amendment T1 for Partner Project Agreement P-004, which commenced on May 1, 2018; with Amendment T2 for Partner Project Agreement P-004, which commenced on May 1, 2018; with Amendment U for Partner Project Agreement P-004, which commenced on September 16, 2018; with Amendment U1 for Partner Project Agreement P-004, which commenced on September 16, 2018; with Amendment U2 for Partner Project Agreement P-004, which commenced on September 16; with Amendment U3 for Partner Project Agreement P-004, which commenced on September 16, 2018; with Amendment V1 for Partner Project Agreement P-004, which commenced on May 1, 2019; with Amendment V2 for Partner Project Agreement P-004, which commenced on May 1, 2019; with Amendment V3 for Partner Project Agreement P-004, which commenced on May 1, 2019, and with Amendment V4 for Partner Project Agreement P-004, which commenced on May 1, 2019; with Amendment W for Partner Project Agreement P-004, which commenced on May 1, 2020; with Amendment W1 for Partner Project Agreement P-004, which commenced on May 1, 2020; with Amendment W2 for Partner Project Agreement P-004, which commenced on May 1, 2020; with Amendment X for Partner Project Agreement P-004, which commenced on May 1, 2021; with Amendment X for Partner Project Agreement P-004, which commenced on May 1, 2021; with Amendment X2 for Partner Project Agreement P-004, which commenced on May 1,



2021; and with Amendment Y for Partner Project Agreement P-004, which commenced on July 1, 2022 as per Article 12 of the Agreement.

This Amendment Y1 prolongs the term of this Agreement until December 31, 2022.

The Partner has agreed to provide financial support for this Amendment Y1.

**Article 2 – Duration of the Project** is hereby amended as follows:

The duration of the Project is increased by 6 months starting from July 1, 2022.

**Article 3 – Financial contribution of the Partner through the Center** is hereby amended as follows:

- 3.1 The total cost of the Project to the Center
- 3.3 The amount of cost for equipment, materials and other direct costs
- 3.4 The amount of grant payments directly to individual participants in the Project
- 3.5 Overhead to the Recipient, represented by its director
- 3.6 The Center will receive fee for its service

**Article 8 - Special Conditions**

- 8.1 To cover current project expenses related to remuneration: each woman shall be nominally compensated for her time spent filling out the questionnaire.

**Article 13 - Annexes** is hereby amended as follows:

Annex P004Y1-P-budgetEN - Work plan supplements previous Annexes and becomes an integral part of the Agreement.

IN WITNESS WHEREOF, the Center, the Partner, and the Recipient, by their authorized representatives, have executed this Amendment.

For the Center



Curtis Bjelajac

Date of signing July 14, 2022

Executive Director  
Science and Technology Center in Ukraine  
7a Metalistiv Street,  
Kyiv03057, Ukraine  
Tel/Fax: +380(44) 490-7150/45

For the Partner

Elizabeth K. Cahoon -S  
Digitally signed by Elizabeth K. Cahoon -S  
Date: 2022.07.13 15:24:23 -04'00'

Elizabeth Cahoon, PhD

Date of signing \_\_\_\_\_

Project Director  
Radiation Epidemiology Branch  
Division of Cancer Epidemiology and Genetics  
National Cancer Institute  
9609 Medical Center Drive  
Room 7E524 MSC 9778  
Bethesda MD 20892-9778 (USPS only)  
Phone: 240-276-7401  
Fax: 240-276-7840

For the Recipient

Mykola Tronko, Academician

Date of signing \_\_\_\_\_

Project manager

Approved

Mykola Tronko, Academician  
of the National Acad. Med. Sci. Ukraine  
Director of the Institute of Endocrinology  
and Metabolism, Academy of Medical  
Sciences of Ukraine  
Vyshgorodska Str. 69,  
Kyiv04114, Ukraine  
Tel.: +380(44) 430 36 94  
Fax: +380(44) 430 49 49